These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19331584)

  • 1. Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1.
    Kosakovsky Pond SL; Smith DM
    Clin Infect Dis; 2009 May; 48(9):1306-9. PubMed ID: 19331584
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
    Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in france.
    Bouchaud O; Le Moing V; Simon F; Ngo Van P; Perre P; Hocqueloux L; Lebouche B; Carret S; Spire B
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):e67-9. PubMed ID: 21233637
    [No Abstract]   [Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Simon VA;
    IAPAC Mon; 2001 Aug; 7(8):235-7. PubMed ID: 11708276
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.
    Holguín A; Soriano V
    HIV Clin Trials; 2002; 3(5):403-11. PubMed ID: 12407490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic diversity of human immunodeficiency virus-1 isolates in Paraná, Brazil.
    Toledo PV; Carvalho DS; Rossi SG; Brindeiro R; de Queiroz-Telles F
    Braz J Infect Dis; 2010; 14(3):230-6. PubMed ID: 20835505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China.
    Li Y; Gu L; Han Y; Xie J; Wang H; Lv W; Song X; Li Y; Iwamoto A; Ishida T; Li T;
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):289-97. PubMed ID: 25501612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in antiretroviral-naive children newly diagnosed with HIV-1 in Manaus, Amazonas.
    Andrade SD; Sabidó M; Monteiro WM; Benzaken AS; Tanuri A
    J Antimicrob Chemother; 2017 Jun; 72(6):1774-1783. PubMed ID: 28333295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorer immunologic outcome on treatment among patients infected with HIV-1 non-B subtypes compared with subtype B in Singapore.
    Lee LK; Lin L; Chua A; Leo YS; Ng OT
    Clin Infect Dis; 2012 Jun; 54(12):1818-20. PubMed ID: 22423124
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of HIV-1 subtype on the clinical response on HAART.
    Frater J
    J HIV Ther; 2002 Nov; 7(4):92-6. PubMed ID: 12733607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L
    Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy.
    Franzetti M; Violin M; Casazza G; Meini G; Callegaro A; Corsi P; Maggiolo F; Pignataro AR; Paolucci S; Gianotti N; Francisci D; Rossotti R; Filice G; Carli T; Zazzi M; Balotta C
    Clin Microbiol Infect; 2012 Mar; 18(3):E66-70. PubMed ID: 22192680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.
    Hawkins CA; Chaplin B; Idoko J; Ekong E; Adewole I; Gashau W; Murphy RL; Kanki P;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):228-34. PubMed ID: 19644383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1.
    Lacerda HR; Medeiros LB; Cavalcanti AM; Ximenes RA; Albuquerque Mde F
    Mem Inst Oswaldo Cruz; 2007 Sep; 102(6):693-9. PubMed ID: 17923997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy.
    Palmisano L; Galluzzo CM; Giuliano M
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):233-4. PubMed ID: 19465827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.